

“gender identity”; and “sex stereotypes”);

2. update statutory citations where needed and include pinpoint citations to religious nondiscrimination authorities;

3. add a definition of “program or activity” consistent with the Civil Rights Restoration Act;

4. include a specific reference to the False Claims Act in light of compliance constituting a material condition of receipt of federal funds; and

5. make clear the form applies to both applicants and recipients.

*Respondents:* Entities applying for or receiving federal financial assistance from the Department of Health and Human Services.

**Estimated Annualized Burden Hours**

**ESTIMATED ANNUALIZED BURDEN HOURS**

Type of respondent	Form name	Number of respondents	Number responses per respondent	Avg. burden/response (in hours)	Total burden hours
States, certain health care providers, other persons, and entities.	Form HHS-690 .....	8,486	1	4	33,944
<b>Total</b> .....	.....	<b>8,486</b>	.....	.....	<b>33,944</b>

**Estimated Annual Burden Costs**

The labor cost reflects the time a lawyer and a chief executive spend reviewing and signing Form HHS-690. Base hourly wages are from the Bureau of Labor Statistics (BLS) May 2023 Occupational Employment and Wage Statistics (OEWS):

- Lawyer (SOC 23-1011): \$84.84/hr.
- Chief Executive (SOC 11-1011): \$124.47/hr.

*Weighted average hourly wage (75% lawyer, 25% chief executive):* \$94.75/hr.

*Fully loaded wage rate with 31% benefits:* \$124.12/hr.

*Per-respondent labor cost (4 hours × \$124.12):* \$496.48.

*Total annualized cost across 8,486 respondents:* \$4,213,379.28.

Cost component	Rate/value
Loaded wage rate .....	\$124.12/hr.
Hours per respondent	4 hrs.
Labor cost per respondent.	\$496.48.
Total respondents .....	8,486.
Total annual labor cost.	\$4,213,379.28.

*Frequency:* The Applicant/Recipient provides this Assurance of Compliance when it applies for or receives new HHS funds.

**Catherine Howard,**

*Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary.*

[FR Doc. 2026-08092 Filed 4-23-26; 8:45 am]

**BILLING CODE 4153-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute on Drug Abuse; Notice of Meeting**

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council on Drug Abuse.

The meeting will be held as a hybrid meeting and is open to the public, as indicated below. Individuals who plan to view the virtual meeting and need special assistance such as sign language interpretation or other reasonable accommodations to view the meeting, should notify Dr. Gillian Acca via email at [gillian.acca@nih.gov](mailto:gillian.acca@nih.gov) ten days in advance of the meeting. The open session of the meeting can be accessed from the NIH Videocast at the following link: (<http://videocast.nih.gov/>).

A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council on Drug Abuse.

*Date:* May 5, 2026.

*Closed:* 10:30 a.m. to 12:15 p.m.

*Agenda:* To review and evaluate grant applications.

*Open:* 1:30 p.m. to 4:30 p.m.

*Agenda:* Presentations and other business of the Council.

*Meeting Format:* Hybrid Meeting.

*Place:* National Institutes of Health, Neuroscience Building, 6001 Executive Boulevard, Room 1135/45/55, Rockville, MD 20852.

*Contact Person:* Susan R.B. Weiss, Ph.D., Director Division of Extramural Research, Office of the Director, National Institute on Drug Abuse, NIH, Three White Flint North, Rm. 09D08, 11601 Landsdown Street, Bethesda, MD 20852, 301-443-6480, [sweiss@nida.nih.gov](mailto:sweiss@nida.nih.gov).

*Contact Person:* Gillian Acca, Ph.D., Health Scientist Administrator, Division of Extramural Research, Office of Extramural Policy, National Institute on Drug Abuse, NIH, Three White Flint North, Rm. 09C70, 11601 Landsdown Street, Bethesda, MD 20852, 301-827-5863, [gillian.acca@nih.gov](mailto:gillian.acca@nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to Dr. Gillian Acca via email at [gillian.acca@nih.gov](mailto:gillian.acca@nih.gov). The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute’s/Center’s home page: [www.drugabuse.gov/NACDA/NACDAHome.html](http://www.drugabuse.gov/NACDA/NACDAHome.html), where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: April 21, 2026.

**David W. Freeman,**

*Supervisory Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2026-08019 Filed 4-23-26; 8:45 am]

**BILLING CODE 4167-05-P**